Brokerage sentiment across the pharmaceutical and emerging workspace sectors remains broadly optimistic, with firms such as Citi and Choice Institutional Equities highlighting robust growth drivers and improving earnings visibility for key players.Citi continues to back large-cap pharma names like Lupin and Sun Pharma, citing strong momentum in their US businesses, healthy product pipelines, and structural…
Indian stocks ended flat with a negative bias on Friday, with the Sensex and the Nifty swinging between red and green as investors locked in gains near record territory and weighed expectations of potential interest-rate cuts in both the U.S. and India alongside incoming domestic growth signals. The S&P BSE Sensex edged down 13.7 points,…
Bank Nifty closed the week at 58,518, up 641 points, and has formed a bullish candle on the weekly chart, signalling a positive bias. After breaking above horizontal resistance at 57,600, the index is consolidating in the 58,600–57,600 band, with a sustained move above 58,600 likely to push it towards 59,000–59,500 and a break below…
Several Indian pharmaceutical companies including Glenmark, Granules India, Sun Pharma, Zydus and Unichem are recalling medicines from the US market, according to the US Food and Drug Administration (USFDA). The recalls are related to manufacturing issues, impurities, and labelling errors, according to the regulator’s latest Enforcement Report. Glenmark Pharmaceuticals is recalling 13,824 tubes of Azelaic Acid Gel,…
Sun Pharmaceutical Industries shares were down by almost 5 per cent in early trade on Friday, May 23. This downturn was prompted by the investors examining the firm’s quarterly balance sheets. The stock dropped to an intraday low of Rs 1,636.60 on the NSE, which is 4.77 percent off the previous close. Subsequently, with a…